Incidence and Neonatal Risk factors of Short Stature and Growth Hormone treatment in Japanese Preterm Infants Born Small for Gestational Age.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
22 08 2019
22 08 2019
Historique:
received:
11
03
2019
accepted:
12
08
2019
entrez:
24
8
2019
pubmed:
24
8
2019
medline:
23
10
2020
Statut:
epublish
Résumé
Incidence and neonatal risk factors for short stature in preterm children born small for gestational age (SGA) have not been fully investigated in Japan. In this prospective study, infants born ≤32 weeks' gestational age (GA) from 2004-2015 were enrolled and followed for 3 years. Incidence of short children born SGA and short stature treated with growth hormone (GH) were investigated. Neonatal risk factors were analysed using univariate and multivariate analyses. GA cut-off value was determined using receiver operating characteristic (ROC) curve analyses. Of 604 infants born ≤32 weeks' GA, 76 (13%) were SGA at birth. Twenty-seven infants (36%) developed short stature at age 2 and 14 infants (19%) received GH treatment at age 3. GA, birthweight, birth length, birth head circumference, and chronic lung disease at 36 weeks' corrected GA were determined as risk factors by univariate analyses (p < 0.01). Multivariate analyses only revealed low GA as an independent risk factor. ROC curve analysis determined a cut-off value of 24 weeks' GA. Nineteen percent of preterm SGA infants ≤32 weeks' GA developed short stature treated with GH. A low GA at birth could be an early detection marker for short stature that requires GH treatment in preterm infants born SGA.
Identifiants
pubmed: 31439925
doi: 10.1038/s41598-019-48785-y
pii: 10.1038/s41598-019-48785-y
pmc: PMC6706397
doi:
Substances chimiques
Human Growth Hormone
12629-01-5
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
12238Références
Front Endocrinol (Lausanne). 2016 Dec 15;7:158
pubmed: 28018293
Arch Dis Child. 1969 Apr;44(234):231-43
pubmed: 5779433
BMJ. 2000 Apr 8;320(7240):967-71
pubmed: 10753147
Clin Pediatr Endocrinol. 2015 Jan;24(1):15-25
pubmed: 25678756
Early Hum Dev. 2007 May;83(5):327-33
pubmed: 16930872
Horm Res. 2004;61(1):33-40
pubmed: 14646400
Horm Res. 1998;49 Suppl 2:7-13
pubmed: 9730665
Pediatr Res. 2005 Feb;57(2):216-22
pubmed: 15585685
J Clin Endocrinol Metab. 2000 Aug;85(8):2816-21
pubmed: 10946888
J Clin Lipidol. 2017 Jul - Aug;11(4):1032-1042
pubmed: 28826566
Pediatr Int. 2016 May;58(5):372-6
pubmed: 26617415
Arch Dis Child. 2015 Mar;100(3):250-4
pubmed: 25260516
Cancer Lett. 2002 Feb 25;176(2):149-58
pubmed: 11804742
Acta Paediatr Suppl. 1997 Nov;423:193-5
pubmed: 9401571
Horm Res Paediatr. 2014;81(4):272-9
pubmed: 24526136
Cochrane Database Syst Rev. 2015 May 27;(5):CD001914
pubmed: 26014160
J Int Med Res. 2018 Feb;46(2):761-772
pubmed: 28974136
Sci Rep. 2016 Dec 09;6:38659
pubmed: 27934914
Pediatr Res. 1995 Aug;38(2):267-71
pubmed: 7478827
Pediatr Res. 1998 Jun;43(6):808-12
pubmed: 9621992
Metabolism. 1974 Oct;23(10):913-9
pubmed: 4370058
Growth Horm IGF Res. 2009 Jun;19(3):198-205
pubmed: 18929499
Biom J. 2005 Aug;47(4):458-72
pubmed: 16161804
J Clin Endocrinol Metab. 2014 Aug;99(8):2683-8
pubmed: 24758180
Am J Hum Biol. 2017 Jul 8;29(4):
pubmed: 28112874
Clin Endocrinol (Oxf). 1994 Nov;41(5):621-30
pubmed: 7828352
Pediatr Res. 1995 Nov;38(5):733-9
pubmed: 8552442
Pediatrics. 2003 Jun;111(6 Pt 1):1253-61
pubmed: 12777538
J Clin Endocrinol Metab. 2007 Mar;92(3):804-10
pubmed: 17200164
Pediatr Res. 1996 Jul;40(1):101-7
pubmed: 8798254
Pediatr Int. 2014 Oct;56(5):702-8
pubmed: 24617834